tetano
Editor, Senior Moderator
Infect Chemother
. 2025 Jul 18.
doi: 10.3947/ic.2025.0027. Online ahead of print. Evaluation of Reactogenicity and Neutralizing Antibody Responses 6 Months Post-Vaccination with Monovalent COVID-19 Vaccine
So Yun Lim[SUP] #[/SUP][SUP] 1 [/SUP], Hye Hee Cha[SUP] #[/SUP][SUP] 1 [/SUP], Ji Yeon Kim[SUP] 1 [/SUP], Ji-Soo Kwon[SUP] 1 [/SUP], Euijin Chang[SUP] 1 [/SUP], Seongman Bae[SUP] 1 [/SUP], Jiwon Jung[SUP] 1 [/SUP], Min Jae Kim[SUP] 1 [/SUP], Yong Pil Chong[SUP] 1 [/SUP], Sang-Ho Choi[SUP] 1 [/SUP], Sang-Oh Lee[SUP] 1 [/SUP], Yang Soo Kim[SUP] 1 [/SUP], Sung-Han Kim[SUP] 2 [/SUP]
Affiliations
The association between reactogenicity and long-term immunogenicity after coronavirus disease 2019 (COVID-19) vaccination remains unclear. This study investigated whether adverse reactions to ChAdOx1 nCoV-19 or BNT162b2 vaccines correlate with neutralizing antibody responses in severe acute respiratory syndrome coronavirus 2 infection-naïve healthcare workers. Blood samples were collected at three time points to measure neutralizing antibodies. Among 123 participants (ChAdOx1 nCoV-19, n = 88; BNT162b2, n = 35), local and systemic reactions were not significantly associated with antibody responses at six months post-vaccination for either vaccine type. No significant interactions between symptoms, time points, or age were observed. These findings suggest that adverse reactions might not predict long-term neutralizing antibody levels following COVID-19 vaccination.
Keywords: Adverse reaction; BNT162b2; COVID-19; ChAdOx1 nCoV-19; Neutralizing antibodies.
. 2025 Jul 18.
doi: 10.3947/ic.2025.0027. Online ahead of print. Evaluation of Reactogenicity and Neutralizing Antibody Responses 6 Months Post-Vaccination with Monovalent COVID-19 Vaccine
So Yun Lim[SUP] #[/SUP][SUP] 1 [/SUP], Hye Hee Cha[SUP] #[/SUP][SUP] 1 [/SUP], Ji Yeon Kim[SUP] 1 [/SUP], Ji-Soo Kwon[SUP] 1 [/SUP], Euijin Chang[SUP] 1 [/SUP], Seongman Bae[SUP] 1 [/SUP], Jiwon Jung[SUP] 1 [/SUP], Min Jae Kim[SUP] 1 [/SUP], Yong Pil Chong[SUP] 1 [/SUP], Sang-Ho Choi[SUP] 1 [/SUP], Sang-Oh Lee[SUP] 1 [/SUP], Yang Soo Kim[SUP] 1 [/SUP], Sung-Han Kim[SUP] 2 [/SUP]
Affiliations
- PMID: 40784737
- DOI: 10.3947/ic.2025.0027
The association between reactogenicity and long-term immunogenicity after coronavirus disease 2019 (COVID-19) vaccination remains unclear. This study investigated whether adverse reactions to ChAdOx1 nCoV-19 or BNT162b2 vaccines correlate with neutralizing antibody responses in severe acute respiratory syndrome coronavirus 2 infection-naïve healthcare workers. Blood samples were collected at three time points to measure neutralizing antibodies. Among 123 participants (ChAdOx1 nCoV-19, n = 88; BNT162b2, n = 35), local and systemic reactions were not significantly associated with antibody responses at six months post-vaccination for either vaccine type. No significant interactions between symptoms, time points, or age were observed. These findings suggest that adverse reactions might not predict long-term neutralizing antibody levels following COVID-19 vaccination.
Keywords: Adverse reaction; BNT162b2; COVID-19; ChAdOx1 nCoV-19; Neutralizing antibodies.